ATCOR

ATCOR develops innovative medical devices and digital solutions that help identify and reduce the risk of hypertension, cardiovascular disease (CVD), and other related vascular disorders. Early detection with SphygmoCor® technology allows clinicians to detect target organ damage and manage cardiovascular disease, Alzheimer's, kidney failure, and other vascular diseases. Using SphygmoCor® technology, researchers and clinicians are able to collect and assess clinically relevant digital vascular biomarkers to facilitate routine patient monitoring. These measurements shed insight into subclinical changes in the arterial system that demonstrate the efficacy of clinical trial therapies for chronic vascular diseases. Digital vascular biomarkers provide better prognostic and diagnostic information to target interventions—complementary and additive to—standard brachial blood pressure measurements. For over twenty years, major medical and research institutions have been using SphygmoCor® systems to improve therapeutics and treatment strategies for the world's most devastating chronic diseases. Leading pharmaceutical companies utilize ATCOR devices to collect primary, secondary, and safety endpoint data across all phases of global clinical trials. Playing an integral role in over 4000+ studies to date, our technology has been referenced in over 7000 citations in leading medical journals. ATCOR is a subsidiary of the Australian listed company Cardiex Limited (ASX:CDX) www.cardiex.com

• Employees 17
• Founded 1993
• Annual Revenue $4327000
• Total Funding $2200000